These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 9655362)

  • 1. Effect of hyperparathyroidism on response to erythropoietin in children on dialysis.
    Belsha CW; Berry PL
    Pediatr Nephrol; 1998 May; 12(4):298-303. PubMed ID: 9655362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of renal anemia in children and adolescents with recombinant human erythropoietin (rHuEPO).
    Campos A; Garin EH
    Clin Pediatr (Phila); 1992 Feb; 31(2):94-9. PubMed ID: 1544282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does parathyroid hormone affect erythropoietin therapy in dialysis patients?
    Al-Hilali N; Al-Humoud H; Ninan VT; Nampoory MR; Puliyclil MA; Johny KV
    Med Princ Pract; 2007; 16(1):63-7. PubMed ID: 17159367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
    Raja R; Bloom E; Johnson R; Goldstein M
    Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities.
    House AA; Pham B; Pagé DE
    Nephrol Dial Transplant; 1998 Jul; 13(7):1763-9. PubMed ID: 9681725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of influence of recombinant human erythropoietin on parathyroid function in hemodialysis patients with secondary hyperparathyroidism.
    Lai YH; Tsai JC; Chen HC; Guh JY; Hwang SJ; Tsai JH
    Nephron; 1995; 70(2):223-8. PubMed ID: 7566308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis.
    Sinai-Trieman L; Salusky IB; Fine RN
    J Pediatr; 1989 Apr; 114(4 Pt 1):550-4. PubMed ID: 2926567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.
    Movilli E; Cancarini GC; Zani R; Camerini C; Sandrini M; Maiorca R
    Nephrol Dial Transplant; 2001 Jan; 16(1):111-4. PubMed ID: 11209002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of adynamic bone disease on responsiveness to recombinant human erythropoietin in peritoneal dialysis patients.
    Kcomt J; Sotelo C; Raja R
    Adv Perit Dial; 2000; 16():294-6. PubMed ID: 11045314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients.
    Gaughan WJ; Liss KA; Dunn SR; Mangold AM; Buhsmer JP; Michael B; Burke JF
    Am J Kidney Dis; 1997 Oct; 30(4):495-500. PubMed ID: 9328363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients.
    DeVita MV; Frumkin D; Mittal S; Kamran A; Fishbane S; Michelis MF
    Clin Nephrol; 2003 Nov; 60(5):335-40. PubMed ID: 14640239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous iron dextran and erythropoietin use in pediatric hemodialysis patients.
    Greenbaum LA; Pan CG; Caley C; Nelson T; Sheth KJ
    Pediatr Nephrol; 2000 Sep; 14(10-11):908-11. PubMed ID: 10975297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis.
    Shrivastava D; Rao TK; Sinert R; Khurana E; Lundin AP; Friedman EA
    Am J Kidney Dis; 1995 Jun; 25(6):904-9. PubMed ID: 7771487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ITDI is the preferred treatment for iron supplementation in rHuEpo-treated anemic PD patients.
    Ahsan N
    Adv Perit Dial; 1998; 14():228-31. PubMed ID: 10649730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anemia in peritoneal dialysis patients].
    Lausević M; Nesić V; Jovanović N; Stojimirović B
    Srp Arh Celok Lek; 2006; 134(3-4):133-7. PubMed ID: 16915754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia?
    Eschbach JW; Varma A; Stivelman JC
    Nephrol Dial Transplant; 2002; 17 Suppl 5():2-7. PubMed ID: 12091599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous recombinant human erythropoietin in children with renal anemia on continuous ambulatory peritoneal dialysis.
    Aufricht C; Balzar E; Steger H; Lothaller MA; Frenzel K; Kohlhauser C; Kiss H; Khoss AE; Kernova T
    Acta Paediatr; 1993 Nov; 82(11):959-62. PubMed ID: 8111178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients.
    Nissenson AR; Berns JS; Sakiewicz P; Ghaddar S; Moore GM; Schleicher RB; Seligman PA
    Am J Kidney Dis; 2003 Aug; 42(2):325-30. PubMed ID: 12900815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of iron saturation for erythropoietin responsiveness in chronic peritoneal dialysis.
    Jonnalagadda V; Bloom EJ; Raja RM
    Adv Perit Dial; 1997; 13():113-5. PubMed ID: 9360662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.